Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma

Acta Neuropathologica

Volumn 128, Issue 4, 2014, Pages 561-571

  Wiestler, Benedikt ^a,b   Capper, David ^a,b   Sill, Martin ^a   Jones, David T W ^a   Hovestadt, Volker ^a   Sturm, Dominik ^a   Koelsche, Christian ^a,b   Bertoni, Anna ^a   Schweizer, Leonille ^a,b   Korshunov, Andrey ^a,b   Weiß, Elisa K ^a,b   Schliesser, Maximilian G ^a   Radbruch, Alexander ^b   Herold Mende, Christel ^b   Roth, Patrick ^g   Unterberg, Andreas ^b   Hartmann, Christian ^a,b,c   Pietsch, Torsten ^d   Reifenberger, Guido ^e,f   Lichter, Peter ^a   Radlwimmer, Bernhard ^a   Platten, Michael ^a,b   Pfister, Stefan M ^a,b   von Deimling, Andreas ^a,b   Weller, Michael ^g   Wick, Wolfgang ^a,b   more..

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

^e HEINRICH HEINE UNIVERSITY   (Germany)

^f DKTK   (Germany)

^g UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

1p 19q; 450 k; Anaplastic glioma; G CIMP; IDH

Indexed keywords

ATRX PROTEIN, HUMAN; DNA HELICASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; NUCLEAR PROTEIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TELOMERASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; BRAIN TUMOR; CHROMOSOME 1; CHROMOSOME 19; CHROMOSOME DELETION; CLASSIFICATION; COPY NUMBER VARIATION; CPG ISLAND; DNA METHYLATION; FEMALE; GENETICS; GERMANY; GLIOMA; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MUTATION;

ADULT; BRAIN NEOPLASMS; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; CPG ISLANDS; DNA COPY NUMBER VARIATIONS; DNA HELICASES; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GERMANY; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; TELOMERASE; TUMOR SUPPRESSOR PROTEINS;

EID: 84929999099     PISSN: 00016322     EISSN: 14320533     Source Type: Journal    
DOI: 10.1007/s00401-014-1315-x     Document Type: Article

References (34)

1. Bady P, Sciuscio D, Diserens A-C, Bloch J, van den Bent MJ et al (2012) MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol 124:547–560
2. Van den Bent MJ, Brandes AA, Taphoorn MJB, Kros JM, Kouwenhoven MCM et al (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350
3. Bettegowda C, Agrawal N, Jiao Y, Sausen M, Wood LD et al (2011) Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 333:1453–1455
4. Brennan CW, Verhaak RGW, McKenna A, Campos B, Noushmehr H et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462–477
5. Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343
6. Christensen BC, Smith AA, Zheng S, Koestler DC, Houseman EA et al (2011) DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. J Natl Cancer Inst 103:143–153
7. Erdem-Eraslan L, Gravendeel LA, de Rooi J, Eilers PHC, Idbaih A et al (2013) Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC stu. J Clin Oncol 31:328–336
8. Frattini V, Trifonov V, Chan JM, Castano A, Lia M et al (2013) The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 45:1141–1149
9. Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120:707–718
10. Heaphy CM, de Wilde RF, Jiao Y, Klein AP, Edil BH et al (2011) Altered telomeres in tumors with ATRX and DAXX mutations. Science 333:425
11. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N et al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci USA 110:6021–6026
12. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D et al (2013) Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. Acta Neuropathol 126:907–915
13. Kros JM, Gorlia T, Kouwenhoven MC, Zheng P–P, Collins VP et al (2007) Panel review of anaplastic oligodendroglioma from European Organization For Research and Treatment of Cancer Trial 26951: assessment of consensus in diagnosis, influence of 1p/19q loss, and correlations with outcome. J Neuropathol Exp Neurol 66:545–551
14. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE et al (2011) Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol 29:4482–4490
15. Liu X-Y, Gerges N, Korshunov A, Sabha N, Khuong-Quang D-A et al (2012) Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. Acta Neuropathol 124:615–625
16. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC et al (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109
17. Mur P, Mollejo M, Ruano Y, de Lope ÁR, Fiaño C et al (2013) Codeletion of 1p and 19q determines distinct gene methylation and expression profiles in IDH-mutated oligodendroglial tumors. Acta Neuropathol 126:277–289
18. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K et al (2010) Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17:510–522
19. Parsons DW, Jones S, Zhang X, Lin JC-H, Leary RJ et al (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812
20. R Core Team (2013) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/
21. Schwartzentruber J, Korshunov A, Liu X-Y, Jones DTW, Pfaff E et al (2012) Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482:226–231
22. Smith JS, Perry A, Borell TJ, Lee HK, O’Fallon J et al (2000) Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol 18:636–645
23. Sturm D, Bender S, Jones DTW, Lichter P, Grill J et al (2014) Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat Rev Cancer 14:92–107
24. Sturm D, Witt H, Hovestadt V, Khuong-Quang D-A, Jones DTW et al (2012) Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell 22:425–437
25. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F et al (2012) IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483:479–483
26. Verhaak RGW, Hoadley KA, Purdom E, Wang V, Qi Y et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17:98–110
27. Ward PS, Patel J, Wise DR, Abdel-Wahab O, Bennett BD et al (2010) The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225–234
28. Wick W, Hartmann C, Engel C, Stoffels M, Felsberg J et al (2009) NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 27:5874–5880
29. Wick W, Meisner C, Hentschel B, Platten M, Schilling A et al (2013) Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology 81:1515–1522
30. Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G et al (2012) Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 13:707–715
31. Wick W, Weller M, van den Bent M, Sanson M, Weiler M et al (2014) MGMT testing in neurooncology—a paradigm for prospects and challenges of biomarker-based treatment decisions. Nat Rev Neurol (in press)
32. Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A et al (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126:443–451
33. Wiestler B, Claus R, Hartlieb SA, Schliesser MG, Weiss EK et al (2013) Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective. Neuro Oncol 15:1017–1026
34. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773